Product Description
| Download Documents | |
| Product Sheet | |
| SDS | COA Lot S585.S8.0306E |
SN38, the active metabolite of irinotecan, is a chemotherapeutic agent primarily used for colorectal cancer treatment. As a topoisomerase I inhibitor, SN38 interferes with DNA replication, ultimately leading to cancer cell death. The BSA-SN38 conjugate is designed using linker chemistry similar to that of ADCs and PDCs which can be produced using our SN38 Conjugation Kits (Cat#: CM11408, CM11430). It is synthesized at CellMosaic and intended for immunization or immunoassay applications. The final conjugate is lyophilized from a citrate buffer for convenient shipping, storage, and reconstitution
The product is sold as either 1 vial of 1 mg (Cat# CM52149-1MG) or 5 vials of 1 mg (Cat# CM52149-5MG). For bulk orders, please contact us for a quote.
Application
- Assay development for detection of SN38 or SN38 metabolites in vitro or in vivo.
- Antibody discovery via immunization and hapten recognition
- Indirect and competitive ELISA assay
Key Features
- Lyophilized powder and ready for usage after reconstitution with water, no need for external buffer.
- Optimized loading with an average 3 to 5 SN38 molecules per BSA
- Amount accurately determined by UV/HPLC analysis.
